-
CCG-1423: RhoA Inhibitor Mechanism & Workflow
2026-08-28
CCG-1423 is a research-use RhoA inhibitor that suppresses MRTF-A nuclear import by disrupting its interaction with importin α/β1. Its documented applications include cancer research, invasion studies, apoptosis assays, and mechanistic analysis of RhoA transcriptional signaling, while direct antiviral activity remains unestablished.
-
Exercise, Muscle EVs, and Microglial Aβ Clearance
2026-08-28
This study identifies skeletal muscle-derived extracellular vesicles as a mechanistic link between swimming exercise and improved cognition in Alzheimer’s disease mice. Its results connect the vesicular miR-378a-3p–p110α pathway to disease-associated microglial function and amyloid-β plaque clearance, suggesting an exercise-mimicking strategy for preclinical Alzheimer’s disease research.
-
DAPT (GSI-IX): A Causal Tool for Angiogenesis
2026-08-27
DAPT (GSI-IX) is more than a Notch signaling pathway inhibitor: it is a causal perturbation tool for separating γ-secretase-dependent effects from downstream angiogenic phenotypes. This article translates a critical limb ischemia study into practical assay design, controls, and interpretation strategies.
-
Faropenem Transport via Renal Npt1
2026-08-27
The reference study identified the mouse inorganic phosphate transporter Npt1 as a chloride-sensitive luminal pathway for faropenem transport in renal epithelial cells. Its Xenopus oocyte experiments connect transporter affinity, directional efflux, and β-lactam competition, providing a mechanistic framework for interpreting renal elimination of penem antibiotics.
-
Calcium Modulation of Amyloid-β Aggregation
2026-08-26
The 2024 PCCP study used supercritical-angle Raman and fluorescence spectroscopy and microscopy to examine how CaCl2 changes amyloid-β aggregation at lipid membrane interfaces. Its central finding is that calcium can protect membranes from peptide insertion, while its effect depends on aggregation timing and is more pronounced for Aβ1–42 than for Aβ1–40.
-
Calpain Inhibitor II, ALLM: Mechanism & Uses
2026-08-26
Calpain Inhibitor II, also called ALLM, is a cell-permeable peptide inhibitor for calpain I, calpain II, cathepsin L, and cathepsin B. Its strongest reported affinity is for cathepsin L, while leukemia and lymphoma studies support its use as a concentration-dependent apoptosis inducer and protease biology tool.
-
Aurora A, SAM Metabolism, and Trained Immunity
2026-08-25
Li et al. identify Aurora kinase A as a metabolic–epigenetic regulator of β-glucan-trained immunity, linking the mTOR–FOXO3–GNMT axis to endogenous S-adenosylmethionine availability and inflammatory chromatin states. The study shows that Aurora A inhibition weakens cytokine recall responses and removes the tumor-suppressive effect of trained immunity in mice, providing a mechanistic framework for connecting cancer biology with innate immune memory.
-
Dibutyryl-cAMP in Astrocyte Reprogramming
2026-08-25
A translational framework for evaluating Dibutyryl-cAMP, sodium salt as a mechanistic perturbation tool in astrocyte-to-motoneuron reprogramming, grounded in recent 4F-cocktail evidence and designed to separate signaling effects from cell-state and maturation outcomes.
-
Steroid Lysis of Protoplasts: A 1965 Mechanistic Study
2026-08-24
Smith and Shay used osmotically fragile Sarcina lutea protoplasts to separate direct membrane lysis from effects mediated by the bacterial cell wall. Their protection and antagonist experiments indicated that synthetic steroid antimicrobials act chiefly at the membrane, while also demonstrating how osmotic stabilization, polyamines, metals, and surfactants can reshape apparent antimicrobial activity.
-
Moxidectin–Polyenes Against Oral Candidiasis
2026-08-24
A 2024 study shows that moxidectin can potentiate amphotericin B and nystatin by increasing Candida albicans ergosterol biosynthesis, thereby strengthening polyene binding and antifungal activity. Genetic, transcriptomic, biochemical, and mouse-model data support an ergosterol-dependent combination strategy for oral candidiasis research, while clinical translation remains unresolved.
-
Ferritin Hybrid Vaccine for Influenza and COVID-19
2026-08-23
The reference study develops a ferritin-based hybrid protein particle that co-displays influenza A M2e and SARS-CoV-2 S-protein tandem epitopes from a coordinated Escherichia coli expression system. In mice, the hybrid particle improved antigen-specific immune responses and produced sera with pseudovirus-inhibitory, cell-binding, and ADCC-associated activity, supporting ferritin as a practical scaffold for combination vaccine design.
-
Filipin III for Reliable Cholesterol Assays
2026-08-22
Learn how Filipin III, SKU B6034, can add a cholesterol-focused mechanistic readout to cell viability, proliferation, and cytotoxicity workflows. This scenario-based guide covers assay interpretation, compatibility, handling, protocol controls, and practical vendor-selection criteria without overstating what the reagent can validate.
-
TLS, TRAF2 Competition, and B-Cell Activation in ESCC
2026-08-22
The reference study identifies tertiary lymphoid structures as an independent favorable prognostic feature in treatment-naive esophageal squamous cell carcinoma and links them to IRF4-positive B-cell activation. Its mechanistic advance is the demonstration that CD40 and STING compete for TRAF2, coupling altered STING ubiquitination and phosphorylation to non-canonical NF-κB signaling and IRF4 induction.
-
Amphotericin B for Biofilm Resistance Research
2026-08-21
Amphotericin B offers a practical way to connect fungal membrane injury with Candida albicans biofilm resistance, autophagy, and inflammatory signaling. This workflow combines concentration-controlled susceptibility assays with the PP2A–Atg pathway framework reported in recent biofilm research.
-
Amyloid β-Peptide (1-42) Workflow Guide
2026-08-20
Build more reproducible Alzheimer’s models by separating Aβ42 aggregation state, neuronal toxicity, microglial clearance, and ion-channel effects. This practical guide combines product-handling controls with a P2Y2-centered microglial workflow for more informative assay design.